Richmond Neal J, Silverman Robert, Kusick Monique, Matallana Luis, Winokur Jules
Department of Emergency Medicine, Long Island Jewish Medical Center, New Hyde Park, NY 11042, USA.
Acad Emerg Med. 2005 May;12(5):396-403. doi: 10.1197/j.aem.2004.12.013.
Each year, approximately 40,000 patients with acute asthma are transported by the Fire Department of New York City (NYC) Emergency Medical Services (EMS). Out-of-hospital administration of bronchodilator therapy has, however, been restricted by scope of practice to advanced life support (ALS) providers. Since the rapid availability of ALS units cannot always be assured, some individuals with acute asthma may receive only basic life support (BLS) measures in the field.
To demonstrate that basic emergency medical technicians (EMT-Bs) are able to effectively administer nebulized albuterol to asthma patients in the out-of-hospital environment.
This was a prospective, observational cohort study of 9-1-1 asthma calls received by the NYC EMS system for patients between the ages of 1 and 65 years. Baseline peak expiratory flow rate (PEFR) and other clinical measures were obtained prior to and following BLS administration of one or two treatments with nebulized albuterol.
Data were available for 3,351 patients over a one-year study period. One out-of-hospital albuterol treatment was given in 60%, while 40% of the patients received two. The PEFRs increased from 40.4% predicted (SD +/-21.0) to 54.8% predicted (SD +/-26.1), for a posttreatment improvement of 14.4% points (95% CI = 13.8 to 15.1). Other clinical outcome measures, including dyspnea index, respiratory rate, and use of accessory muscles, also showed improvement.
This study demonstrates that EMT-Bs can effectively administer albuterol to acute asthma patients in the out-of-hospital environment.
每年,纽约市消防局紧急医疗服务(EMS)运送约40000例急性哮喘患者。然而,院外支气管扩张剂治疗的实施范围仅限于高级生命支持(ALS)人员。由于无法始终确保ALS单位能迅速到位,一些急性哮喘患者在现场可能仅接受基本生命支持(BLS)措施。
证明基本急救医疗技术员(EMT-B)能够在院外环境中有效地为哮喘患者雾化吸入沙丁胺醇。
这是一项前瞻性观察队列研究,研究对象为纽约市EMS系统接到的1至65岁哮喘患者的9-1-1急救呼叫。在BLS给予一或两次雾化沙丁胺醇治疗之前和之后,获取基线呼气峰值流速(PEFR)和其他临床指标。
在为期一年的研究期间,有3351例患者的数据可用。60%的患者接受了一次院外沙丁胺醇治疗,40%的患者接受了两次。PEFR从预计值的40.4%(标准差±21.0)增至预计值的54.8%(标准差±26.1),治疗后改善了14.4个百分点(95%CI = 13.8至15.1)。其他临床结局指标,包括呼吸困难指数、呼吸频率和辅助肌使用情况,也显示有所改善。
本研究表明,EMT-B能够在院外环境中有效地为急性哮喘患者施用沙丁胺醇。